The epidemiology of carbapenem resistance in Acinetobacter baumannii complex in Germany (2014-2018): an analysis of data from the national Antimicrobial Resistance Surveillance system

Carbapenem-resistant Acinetobacter baumannii complex (CRABC) has globally emerged as a serious public health challenge. This study aimed to describe epidemiological trends and risk factors of carbapenem resistance in A. baumannii complex isolates in Germany between 2014 and 2018. We analysed 43,948...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial resistance & infection control 2021-03, Vol.10 (1), p.45-13, Article 45
Main Authors: Said, Dunja, Willrich, Niklas, Ayobami, Olaniyi, Noll, Ines, Eckmanns, Tim, Markwart, Robby
Format: Article
Language:English
Subjects:
Acinetobacter baumannii complex
Analysis
Antibacterial agents
Antibiotics
Antimicrobial agents
Antimicrobial resistance
ARS
Carbapenem resistance
Disease control
Drug resistance
Drug resistance in microorganisms
Epidemiology
Gender
Health aspects
Hospitals
Infections
Intensive care
Laboratories
Outpatient care facilities
Pathogens
Patients
Public health
Risk factors
Surveillance
Urine
Variables
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c610t-59228ac579c0b8af460e503ade3c2ae9206ea25e847ac81d165b7b1b84245c663
cites cdi_FETCH-LOGICAL-c610t-59228ac579c0b8af460e503ade3c2ae9206ea25e847ac81d165b7b1b84245c663
container_end_page 13
container_issue 1
container_start_page 45
container_title Antimicrobial resistance & infection control
container_volume 10
creator Said, Dunja
Willrich, Niklas
Ayobami, Olaniyi
Noll, Ines
Eckmanns, Tim
Markwart, Robby
description Carbapenem-resistant Acinetobacter baumannii complex (CRABC) has globally emerged as a serious public health challenge. This study aimed to describe epidemiological trends and risk factors of carbapenem resistance in A. baumannii complex isolates in Germany between 2014 and 2018. We analysed 43,948 clinical A. baumannii complex isolates using 2014 to 2018 data from the German Antimicrobial Resistance Surveillance system. We applied descriptive statistics and uni- and multivariable regression analyses to investigate carbapenem resistance in A. baumannii complex isolates. The proportion of carbapenem resistance in clinical A. baumannii complex isolates declined from 7.6% (95% confidence interval [95% CI] 4.4-12.7%) in 2014 to 3.5% (95% CI 2.5-4.7%) in 2018 (adjusted OR [aOR] 0.85 [95% CI 0.79-0.93, p ≤ 0.001]). Higher mean CRABC proportions for 2014 to 2018 were observed in secondary care hospitals (4.9% [95% CI 3.2-7.5%], aOR 3.6 [95% CI 2.4-5.3, p ≤ 0.001]) and tertiary care hospitals (5.9% [95% CI 3.0-11.2%], aOR 5.4 [95% CI 2.9-10.0, p ≤ 0.001) compared to outpatient clinics (1.3% [95% CI 1.1-1.6%]). CRABC proportions in hospitals varied between German regions and ranged between 2.4% (95% CI 1.6-3.5%) in the Southeast and 8.8% (95% CI 4.2-17.3%) in the Northwest. Lower CRABC proportions were observed in younger patients (
doi_str_mv 10.1186/s13756-021-00909-8
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_2edbbecfd81843309417f1b4f7ea6b02</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A655220857</galeid><doaj_id>oai_doaj_org_article_2edbbecfd81843309417f1b4f7ea6b02</doaj_id><sourcerecordid>A655220857</sourcerecordid><originalsourceid>FETCH-LOGICAL-c610t-59228ac579c0b8af460e503ade3c2ae9206ea25e847ac81d165b7b1b84245c663</originalsourceid><addsrcrecordid>eNptkl1rFDEUhgdRrNT-AS8kIIheTE0y-RovhKVoLRQErdchyZzZTZlJ1iRb3F_m3zPbrW0XTEI-Tt7zZCZ5m-YVwaeEKPEhk05y0WJKWox73LfqSfOCYiZb2vfs6aP5UXOS8zWuRUiMVfe8Oeo6wRTv2Yvmz9UKEKz9ALOPU1xuURyRM8maNQSYUYLsczHBAfIBLZwPUKI1rkBC1mxmE4L3yMV5PcHvneQcUg1u0TuKCWtrp95_RCbUZqZtZe34gykGjSnOqNTTgyk-1l20CMXP3qVofV19fzj5xybdgJ-m20Xe5gLzy-bZaKYMJ3fjcfPzy-ers6_t5bfzi7PFZesEwaXlPaXKOC57h60yIxMYOO7MAJ2jBnqKBRjKQTFpnCIDEdxKS6xilHEnRHfcXOy5QzTXep38bNJWR-P1bSCmpTapeDeBpjBYC24cFFGs63DPiByJZaMEIyymlfVpz1pv7AyDg1CSmQ6ghzvBr_Qy3mjZ047JrgLe3AFS_LWBXPR13KR6dVlTjqkUklPyoFqa-lU-jLHC3Oyz0wvBOaVYcVlVp_9R1bpzgosBRl_jBwlvHyWswExlleO02T1ePhTSvbC-ZM4Jxvs_JFjvvKv33tXVu_rWu1rVpNeP7-Y-5Z9Tu79WGepz</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2502767521</pqid></control><display><type>article</type><title>The epidemiology of carbapenem resistance in Acinetobacter baumannii complex in Germany (2014-2018): an analysis of data from the national Antimicrobial Resistance Surveillance system</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Said, Dunja ; Willrich, Niklas ; Ayobami, Olaniyi ; Noll, Ines ; Eckmanns, Tim ; Markwart, Robby</creator><creatorcontrib>Said, Dunja ; Willrich, Niklas ; Ayobami, Olaniyi ; Noll, Ines ; Eckmanns, Tim ; Markwart, Robby</creatorcontrib><description>Carbapenem-resistant Acinetobacter baumannii complex (CRABC) has globally emerged as a serious public health challenge. This study aimed to describe epidemiological trends and risk factors of carbapenem resistance in A. baumannii complex isolates in Germany between 2014 and 2018. We analysed 43,948 clinical A. baumannii complex isolates using 2014 to 2018 data from the German Antimicrobial Resistance Surveillance system. We applied descriptive statistics and uni- and multivariable regression analyses to investigate carbapenem resistance in A. baumannii complex isolates. The proportion of carbapenem resistance in clinical A. baumannii complex isolates declined from 7.6% (95% confidence interval [95% CI] 4.4-12.7%) in 2014 to 3.5% (95% CI 2.5-4.7%) in 2018 (adjusted OR [aOR] 0.85 [95% CI 0.79-0.93, p ≤ 0.001]). Higher mean CRABC proportions for 2014 to 2018 were observed in secondary care hospitals (4.9% [95% CI 3.2-7.5%], aOR 3.6 [95% CI 2.4-5.3, p ≤ 0.001]) and tertiary care hospitals (5.9% [95% CI 3.0-11.2%], aOR 5.4 [95% CI 2.9-10.0, p ≤ 0.001) compared to outpatient clinics (1.3% [95% CI 1.1-1.6%]). CRABC proportions in hospitals varied between German regions and ranged between 2.4% (95% CI 1.6-3.5%) in the Southeast and 8.8% (95% CI 4.2-17.3%) in the Northwest. Lower CRABC proportions were observed in younger patients (&lt; 1 year: 0.6% [95% CI 0.2-1.3%]; 1-19 years: 1.3% [95% CI 0.7-2.5%]) than adults (20-39 years: 7.7% [95% CI 4.4-13.0%]; 40-59 years: 6.2% [4.2-8.9%]; 60-79 years: 5.8% [95% CI 4.0-8.3%]). In the 20-39 year old patient age group, CRABC proportions were significantly higher for men than for women (14.6% [95% CI 8.6-23.6%] vs. 2.5% [95% CI 1.3-4.5%]). A. baumannii complex isolates from lower respiratory infections were more likely to be carbapenem-resistant than isolates from upper respiratory infections (11.4% [95% CI 7.9-16.2%] vs. 4.0% [95% CI 2.7-6.0%]; adjusted OR: 1.5 [95% CI 1.2-1.9, p ≤ 0.001]). In contrast to many other regions worldwide, carbapenem resistance proportions among clinical A. baumannii complex isolates are relatively low in Germany and have declined in the last few years. Ongoing efforts in antibiotic stewardship and infection prevention and control are needed to prevent the spread of carbapenem-resistant A. baumannii complex in Germany.</description><identifier>ISSN: 2047-2994</identifier><identifier>EISSN: 2047-2994</identifier><identifier>DOI: 10.1186/s13756-021-00909-8</identifier><identifier>PMID: 33648594</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Acinetobacter baumannii complex ; Analysis ; Antibacterial agents ; Antibiotics ; Antimicrobial agents ; Antimicrobial resistance ; ARS ; Carbapenem resistance ; Disease control ; Drug resistance ; Drug resistance in microorganisms ; Epidemiology ; Gender ; Health aspects ; Hospitals ; Infections ; Intensive care ; Laboratories ; Outpatient care facilities ; Pathogens ; Patients ; Public health ; Risk factors ; Surveillance ; Urine ; Variables</subject><ispartof>Antimicrobial resistance &amp; infection control, 2021-03, Vol.10 (1), p.45-13, Article 45</ispartof><rights>COPYRIGHT 2021 BioMed Central Ltd.</rights><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c610t-59228ac579c0b8af460e503ade3c2ae9206ea25e847ac81d165b7b1b84245c663</citedby><cites>FETCH-LOGICAL-c610t-59228ac579c0b8af460e503ade3c2ae9206ea25e847ac81d165b7b1b84245c663</cites><orcidid>0000-0003-0338-3433</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923473/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2502767521?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33648594$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Said, Dunja</creatorcontrib><creatorcontrib>Willrich, Niklas</creatorcontrib><creatorcontrib>Ayobami, Olaniyi</creatorcontrib><creatorcontrib>Noll, Ines</creatorcontrib><creatorcontrib>Eckmanns, Tim</creatorcontrib><creatorcontrib>Markwart, Robby</creatorcontrib><title>The epidemiology of carbapenem resistance in Acinetobacter baumannii complex in Germany (2014-2018): an analysis of data from the national Antimicrobial Resistance Surveillance system</title><title>Antimicrobial resistance &amp; infection control</title><addtitle>Antimicrob Resist Infect Control</addtitle><description>Carbapenem-resistant Acinetobacter baumannii complex (CRABC) has globally emerged as a serious public health challenge. This study aimed to describe epidemiological trends and risk factors of carbapenem resistance in A. baumannii complex isolates in Germany between 2014 and 2018. We analysed 43,948 clinical A. baumannii complex isolates using 2014 to 2018 data from the German Antimicrobial Resistance Surveillance system. We applied descriptive statistics and uni- and multivariable regression analyses to investigate carbapenem resistance in A. baumannii complex isolates. The proportion of carbapenem resistance in clinical A. baumannii complex isolates declined from 7.6% (95% confidence interval [95% CI] 4.4-12.7%) in 2014 to 3.5% (95% CI 2.5-4.7%) in 2018 (adjusted OR [aOR] 0.85 [95% CI 0.79-0.93, p ≤ 0.001]). Higher mean CRABC proportions for 2014 to 2018 were observed in secondary care hospitals (4.9% [95% CI 3.2-7.5%], aOR 3.6 [95% CI 2.4-5.3, p ≤ 0.001]) and tertiary care hospitals (5.9% [95% CI 3.0-11.2%], aOR 5.4 [95% CI 2.9-10.0, p ≤ 0.001) compared to outpatient clinics (1.3% [95% CI 1.1-1.6%]). CRABC proportions in hospitals varied between German regions and ranged between 2.4% (95% CI 1.6-3.5%) in the Southeast and 8.8% (95% CI 4.2-17.3%) in the Northwest. Lower CRABC proportions were observed in younger patients (&lt; 1 year: 0.6% [95% CI 0.2-1.3%]; 1-19 years: 1.3% [95% CI 0.7-2.5%]) than adults (20-39 years: 7.7% [95% CI 4.4-13.0%]; 40-59 years: 6.2% [4.2-8.9%]; 60-79 years: 5.8% [95% CI 4.0-8.3%]). In the 20-39 year old patient age group, CRABC proportions were significantly higher for men than for women (14.6% [95% CI 8.6-23.6%] vs. 2.5% [95% CI 1.3-4.5%]). A. baumannii complex isolates from lower respiratory infections were more likely to be carbapenem-resistant than isolates from upper respiratory infections (11.4% [95% CI 7.9-16.2%] vs. 4.0% [95% CI 2.7-6.0%]; adjusted OR: 1.5 [95% CI 1.2-1.9, p ≤ 0.001]). In contrast to many other regions worldwide, carbapenem resistance proportions among clinical A. baumannii complex isolates are relatively low in Germany and have declined in the last few years. Ongoing efforts in antibiotic stewardship and infection prevention and control are needed to prevent the spread of carbapenem-resistant A. baumannii complex in Germany.</description><subject>Acinetobacter baumannii complex</subject><subject>Analysis</subject><subject>Antibacterial agents</subject><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Antimicrobial resistance</subject><subject>ARS</subject><subject>Carbapenem resistance</subject><subject>Disease control</subject><subject>Drug resistance</subject><subject>Drug resistance in microorganisms</subject><subject>Epidemiology</subject><subject>Gender</subject><subject>Health aspects</subject><subject>Hospitals</subject><subject>Infections</subject><subject>Intensive care</subject><subject>Laboratories</subject><subject>Outpatient care facilities</subject><subject>Pathogens</subject><subject>Patients</subject><subject>Public health</subject><subject>Risk factors</subject><subject>Surveillance</subject><subject>Urine</subject><subject>Variables</subject><issn>2047-2994</issn><issn>2047-2994</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkl1rFDEUhgdRrNT-AS8kIIheTE0y-RovhKVoLRQErdchyZzZTZlJ1iRb3F_m3zPbrW0XTEI-Tt7zZCZ5m-YVwaeEKPEhk05y0WJKWox73LfqSfOCYiZb2vfs6aP5UXOS8zWuRUiMVfe8Oeo6wRTv2Yvmz9UKEKz9ALOPU1xuURyRM8maNQSYUYLsczHBAfIBLZwPUKI1rkBC1mxmE4L3yMV5PcHvneQcUg1u0TuKCWtrp95_RCbUZqZtZe34gykGjSnOqNTTgyk-1l20CMXP3qVofV19fzj5xybdgJ-m20Xe5gLzy-bZaKYMJ3fjcfPzy-ers6_t5bfzi7PFZesEwaXlPaXKOC57h60yIxMYOO7MAJ2jBnqKBRjKQTFpnCIDEdxKS6xilHEnRHfcXOy5QzTXep38bNJWR-P1bSCmpTapeDeBpjBYC24cFFGs63DPiByJZaMEIyymlfVpz1pv7AyDg1CSmQ6ghzvBr_Qy3mjZ047JrgLe3AFS_LWBXPR13KR6dVlTjqkUklPyoFqa-lU-jLHC3Oyz0wvBOaVYcVlVp_9R1bpzgosBRl_jBwlvHyWswExlleO02T1ePhTSvbC-ZM4Jxvs_JFjvvKv33tXVu_rWu1rVpNeP7-Y-5Z9Tu79WGepz</recordid><startdate>20210301</startdate><enddate>20210301</enddate><creator>Said, Dunja</creator><creator>Willrich, Niklas</creator><creator>Ayobami, Olaniyi</creator><creator>Noll, Ines</creator><creator>Eckmanns, Tim</creator><creator>Markwart, Robby</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-0338-3433</orcidid></search><sort><creationdate>20210301</creationdate><title>The epidemiology of carbapenem resistance in Acinetobacter baumannii complex in Germany (2014-2018): an analysis of data from the national Antimicrobial Resistance Surveillance system</title><author>Said, Dunja ; Willrich, Niklas ; Ayobami, Olaniyi ; Noll, Ines ; Eckmanns, Tim ; Markwart, Robby</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c610t-59228ac579c0b8af460e503ade3c2ae9206ea25e847ac81d165b7b1b84245c663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acinetobacter baumannii complex</topic><topic>Analysis</topic><topic>Antibacterial agents</topic><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Antimicrobial resistance</topic><topic>ARS</topic><topic>Carbapenem resistance</topic><topic>Disease control</topic><topic>Drug resistance</topic><topic>Drug resistance in microorganisms</topic><topic>Epidemiology</topic><topic>Gender</topic><topic>Health aspects</topic><topic>Hospitals</topic><topic>Infections</topic><topic>Intensive care</topic><topic>Laboratories</topic><topic>Outpatient care facilities</topic><topic>Pathogens</topic><topic>Patients</topic><topic>Public health</topic><topic>Risk factors</topic><topic>Surveillance</topic><topic>Urine</topic><topic>Variables</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Said, Dunja</creatorcontrib><creatorcontrib>Willrich, Niklas</creatorcontrib><creatorcontrib>Ayobami, Olaniyi</creatorcontrib><creatorcontrib>Noll, Ines</creatorcontrib><creatorcontrib>Eckmanns, Tim</creatorcontrib><creatorcontrib>Markwart, Robby</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing &amp; Allied Health Database</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Antimicrobial resistance &amp; infection control</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Said, Dunja</au><au>Willrich, Niklas</au><au>Ayobami, Olaniyi</au><au>Noll, Ines</au><au>Eckmanns, Tim</au><au>Markwart, Robby</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The epidemiology of carbapenem resistance in Acinetobacter baumannii complex in Germany (2014-2018): an analysis of data from the national Antimicrobial Resistance Surveillance system</atitle><jtitle>Antimicrobial resistance &amp; infection control</jtitle><addtitle>Antimicrob Resist Infect Control</addtitle><date>2021-03-01</date><risdate>2021</risdate><volume>10</volume><issue>1</issue><spage>45</spage><epage>13</epage><pages>45-13</pages><artnum>45</artnum><issn>2047-2994</issn><eissn>2047-2994</eissn><abstract>Carbapenem-resistant Acinetobacter baumannii complex (CRABC) has globally emerged as a serious public health challenge. This study aimed to describe epidemiological trends and risk factors of carbapenem resistance in A. baumannii complex isolates in Germany between 2014 and 2018. We analysed 43,948 clinical A. baumannii complex isolates using 2014 to 2018 data from the German Antimicrobial Resistance Surveillance system. We applied descriptive statistics and uni- and multivariable regression analyses to investigate carbapenem resistance in A. baumannii complex isolates. The proportion of carbapenem resistance in clinical A. baumannii complex isolates declined from 7.6% (95% confidence interval [95% CI] 4.4-12.7%) in 2014 to 3.5% (95% CI 2.5-4.7%) in 2018 (adjusted OR [aOR] 0.85 [95% CI 0.79-0.93, p ≤ 0.001]). Higher mean CRABC proportions for 2014 to 2018 were observed in secondary care hospitals (4.9% [95% CI 3.2-7.5%], aOR 3.6 [95% CI 2.4-5.3, p ≤ 0.001]) and tertiary care hospitals (5.9% [95% CI 3.0-11.2%], aOR 5.4 [95% CI 2.9-10.0, p ≤ 0.001) compared to outpatient clinics (1.3% [95% CI 1.1-1.6%]). CRABC proportions in hospitals varied between German regions and ranged between 2.4% (95% CI 1.6-3.5%) in the Southeast and 8.8% (95% CI 4.2-17.3%) in the Northwest. Lower CRABC proportions were observed in younger patients (&lt; 1 year: 0.6% [95% CI 0.2-1.3%]; 1-19 years: 1.3% [95% CI 0.7-2.5%]) than adults (20-39 years: 7.7% [95% CI 4.4-13.0%]; 40-59 years: 6.2% [4.2-8.9%]; 60-79 years: 5.8% [95% CI 4.0-8.3%]). In the 20-39 year old patient age group, CRABC proportions were significantly higher for men than for women (14.6% [95% CI 8.6-23.6%] vs. 2.5% [95% CI 1.3-4.5%]). A. baumannii complex isolates from lower respiratory infections were more likely to be carbapenem-resistant than isolates from upper respiratory infections (11.4% [95% CI 7.9-16.2%] vs. 4.0% [95% CI 2.7-6.0%]; adjusted OR: 1.5 [95% CI 1.2-1.9, p ≤ 0.001]). In contrast to many other regions worldwide, carbapenem resistance proportions among clinical A. baumannii complex isolates are relatively low in Germany and have declined in the last few years. Ongoing efforts in antibiotic stewardship and infection prevention and control are needed to prevent the spread of carbapenem-resistant A. baumannii complex in Germany.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>33648594</pmid><doi>10.1186/s13756-021-00909-8</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0003-0338-3433</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2047-2994
ispartof Antimicrobial resistance & infection control, 2021-03, Vol.10 (1), p.45-13, Article 45
issn 2047-2994
2047-2994
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_2edbbecfd81843309417f1b4f7ea6b02
source Publicly Available Content Database; PubMed Central
subjects Acinetobacter baumannii complex
Analysis
Antibacterial agents
Antibiotics
Antimicrobial agents
Antimicrobial resistance
ARS
Carbapenem resistance
Disease control
Drug resistance
Drug resistance in microorganisms
Epidemiology
Gender
Health aspects
Hospitals
Infections
Intensive care
Laboratories
Outpatient care facilities
Pathogens
Patients
Public health
Risk factors
Surveillance
Urine
Variables
title The epidemiology of carbapenem resistance in Acinetobacter baumannii complex in Germany (2014-2018): an analysis of data from the national Antimicrobial Resistance Surveillance system
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T13%3A00%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20epidemiology%20of%20carbapenem%20resistance%20in%20Acinetobacter%20baumannii%20complex%20in%20Germany%20(2014-2018):%20an%20analysis%20of%20data%20from%20the%20national%20Antimicrobial%20Resistance%20Surveillance%20system&rft.jtitle=Antimicrobial%20resistance%20&%20infection%20control&rft.au=Said,%20Dunja&rft.date=2021-03-01&rft.volume=10&rft.issue=1&rft.spage=45&rft.epage=13&rft.pages=45-13&rft.artnum=45&rft.issn=2047-2994&rft.eissn=2047-2994&rft_id=info:doi/10.1186/s13756-021-00909-8&rft_dat=%3Cgale_doaj_%3EA655220857%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c610t-59228ac579c0b8af460e503ade3c2ae9206ea25e847ac81d165b7b1b84245c663%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2502767521&rft_id=info:pmid/33648594&rft_galeid=A655220857&rfr_iscdi=true